A Phase 3 interventional study of AXS-14 (esreboxetine) in Fibromyalgia, sponsored by Axsome Therapeutics, Inc.. Enrolling by invitation at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.
Among the 369 studies in Fibromyalgia with a site in United States, this one is the 56th largest by planned enrollment of the 320 interventional ones that give a count, is one of 20 that started in 2026, is one of 55 in phase 3, reaches primary completion later than 47 of the 62 other live ones, and was the 363rd registered.
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Spaulding Rehabilitation Hospital · Sites in United States
Ages 21–65
Pulkit Grover · Sites in United States
Ages 18–65
Theranica · Sites in United States, Israel
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 61 · Phase 3 64 · Phase 4 24
First in 1994; this study’s year is marked. 20 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 72 across the 320 interventional studies, 200 across the 47 observational. Of the 276 that completed or were terminated, 116 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 369 have an industry lead sponsor. The 10 most frequent:
Axsome Therapeutics, Inc. is the lead sponsor of 37 studies on the registry; 12 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
Axsome Therapeutics, Inc. has 2 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
29 of the studies in Fibromyalgia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT07116278University of California, San FranciscoTMS-EEG Biomarkers for Chronic Pain | 2026-12 |
| NCT04949100Paul CrawfordMicrocurrent for Fibromyalgia | 2026-12 |
| NCT07525063Duke UniversityPain & Reward Neuromodulation of CNS Circuits | 2026-12 |
| NCT06552728University of California, IrvineThe Effects of Energy Healing in Fibromyalgia | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 369 studies in Fibromyalgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia.
Eligible subjects will have previously participated in the AXS-14-FM-301 (FORWARD) study. Subjects in this open-label extension trial will receive open-label AXS-14 for up to 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Up to 52 weeks.
Drug: AXS-14 (esreboxetine)
AXS-14 tablets taken twice daily.
Long-term Safety
Incidence of treatment-emergent adverse events following dosing with AXS-14
Time frame: Up to 52 weeks.
Plan to share: No
Started Apr 2026 (actual). Primary completion is estimated for May 2028, 25 months after the start.
Of 17 phase 3 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's planned 25 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esreboxetine